(VIANEWS) – Celsius Holdings (CELH), BanColombia S.A. (CIB), Intuitive Surgical (ISRG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Celsius Holdings (CELH)
77.6% sales growth and 16.18% return on equity
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. It also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened name; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery distributors and direct to retailers, include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.48.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 103.4. Meaning, the purchaser of the share is investing $103.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.18%.
Moving Average
Celsius Holdings’s value is below its 50-day moving average of $54.51 and above its 200-day moving average of $46.56.
Volume
Today’s last reported volume for Celsius Holdings is 1919860 which is 60.72% below its average volume of 4888500.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Celsius Holdings’s EBITDA is 10.55.
Sales Growth
Celsius Holdings’s sales growth is 86.7% for the ongoing quarter and 77.6% for the next.
Previous days news about Celsius Holdings(CELH)
- Here is what to know beyond why celsius holdings inc. (celh) is a trending stock. According to Zacks on Thursday, 14 December, "The facts discussed here and much other information on Zacks.com might help determine whether or not it’s worthwhile paying attention to the market buzz about Celsius Holdings Inc. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.", "For Celsius Holdings Inc. the consensus sales estimate for the current quarter of $326.25 million indicates a year-over-year change of +83.3%. "
- According to Zacks on Thursday, 14 December, "We have highlighted three better-ranked stocks, namely MGP Ingredients, Inc. (MGPI Quick QuoteMGPI – Free Report) , Celsius Holdings (CELH Quick QuoteCELH – Free Report) and The Kraft Heinz Company (KHC Quick QuoteKHC – Free Report) .MGP Ingredients produces and markets ingredients and distillery products to the packaged goods industry. "
2. BanColombia S.A. (CIB)
63.8% sales growth and 16.94% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.62.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 4.27. Meaning, the purchaser of the share is investing $4.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.94%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 2.6 and the estimated forward annual dividend yield is 9.42%.
Volume
Today’s last reported volume for BanColombia S.A. is 214900 which is 12.81% below its average volume of 246480.
Moving Average
BanColombia S.A.’s value is above its 50-day moving average of $26.34 and higher than its 200-day moving average of $26.47.
Sales Growth
BanColombia S.A.’s sales growth is 47.5% for the ongoing quarter and 63.8% for the next.
3. Intuitive Surgical (ISRG)
18.7% sales growth and 12.76% return on equity
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Intuitive Surgical has a trailing twelve months EPS of $4.24.
PE Ratio
Intuitive Surgical has a trailing twelve months price to earnings ratio of 76.73. Meaning, the purchaser of the share is investing $76.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.76%.
Volume
Today’s last reported volume for Intuitive Surgical is 1110600 which is 40.38% below its average volume of 1862970.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 19.5% and 19.5%, respectively.
4. Exelixis (EXEL)
18.4% sales growth and 3.8% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.29.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 75.83. Meaning, the purchaser of the share is investing $75.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 355.6% and 58.3%, respectively.
Volume
Today’s last reported volume for Exelixis is 1534440 which is 33.29% below its average volume of 2300320.
Sales Growth
Exelixis’s sales growth is 15.5% for the present quarter and 18.4% for the next.
5. Medpace Holdings (MEDP)
17.8% sales growth and 66.57% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $8.53.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 35.12. Meaning, the purchaser of the share is investing $35.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.57%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 4.7% and 5.7%, respectively.
Sales Growth
Medpace Holdings’s sales growth is 26.6% for the ongoing quarter and 17.8% for the next.
Volume
Today’s last reported volume for Medpace Holdings is 339147 which is 20.97% above its average volume of 280346.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Medpace Holdings’s EBITDA is 5.19.
6. Upwork (UPWK)
14.8% sales growth and 4.44% return on equity
Upwork Inc., together with its subsidiaries, operates a work marketplace that connects businesses with various independent professionals and agencies in the United States, India, the Philippines, and internationally. The company's work marketplace provides access to talent with various skills across a range of categories, including sales and marketing, customer service, data science and analytics, design and creative, web, mobile, and software development. Its work marketplace also enables clients to streamline workflows, such as talent sourcing, outreach, and contracting. The company's work marketplace offers access to various functionalities for remote engagements with talent, including communication and collaboration, ability to receive talent invoices through their work marketplace, and payment protection. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Enterprise, and Upwork Payroll, as well as managed and internet escrow agency services. The company was formerly known as Elance-oDesk, Inc. and changed its name to Upwork Inc. in May 2015. Upwork Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Upwork has a trailing twelve months EPS of $-0.19.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.44%.
Volume
Today’s last reported volume for Upwork is 800864 which is 61.61% below its average volume of 2086350.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 325% and 1400%, respectively.
7. Copart (CPRT)
9.5% sales growth and 23.46% return on equity
Copart, Inc. provides online auctions and vehicle remarketing services in the United States, Canada, the United Kingdom, Brazil, the Republic of Ireland, Germany, Finland, the United Arab Emirates, Oman, Bahrain, and Spain. It offers a range of services for processing and selling vehicles over the internet through its virtual bidding third generation internet auction-style sales technology to vehicle sellers, insurance companies, banks and finance companies, charities, fleet operators, dealers, vehicle rental companies, and individuals. The company's services include online seller access, salvage estimation, estimating, end-of-life vehicle processing, transportation, vehicle inspection stations, on-demand reporting, title processing and procurement, loan payoff, flexible vehicle processing programs, buy it now, member network, sales process, and dealer services. Its services also comprise services to sell vehicles through CashForCars.com, CashForCars.ca, CashForCars.de, CashForCars.co.uk, and Cash-for-cars.ie; Copart Recycling service, which allows the public to purchase parts from salvaged and end-of-life vehicles; copart 360, an online technology for posting vehicle images that captures clear 360-degree views of interiors and exteriors of cars, trucks, and vans; membership tiers for those registering to buy vehicles through Copart.com; and virtual queue to secure a place in line while visiting one of its locations. In addition, it provides non-salvage powersport vehicle remarketing services through live and online auction platforms. The company sells its products principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, and exporters, as well as to the public. Copart, Inc. was incorporated in 1982 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Copart has a trailing twelve months EPS of $1.37.
PE Ratio
Copart has a trailing twelve months price to earnings ratio of 35.84. Meaning, the purchaser of the share is investing $35.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.46%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 4B for the twelve trailing months.
Sales Growth
Copart’s sales growth for the next quarter is 9.5%.
Moving Average
Copart’s worth is above its 50-day moving average of $47.28 and way higher than its 200-day moving average of $43.27.
Yearly Top and Bottom Value
Copart’s stock is valued at $49.10 at 14:22 EST, below its 52-week high of $51.53 and way higher than its 52-week low of $29.61.
